LONDON--(BUSINESS WIRE)--Technavio has announced their latest pipeline analysis report on the Behcet's syndrome market. The report includes a detailed analysis of the pipeline molecules under ...

LONDON--(BUSINESS WIRE)--According to a recent Technavio report, the Behcet's disease therapeutics market is expected to grow by USD 224.55 million during 2019-2023. Growth in the Behcet's disease ...

(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...

DESTIN, Fla. — Behçet syndrome — which is classified as a vasculitis — is marked by distinct features that differentiate it from other autoimmune and autoinflammatory diseases, according to Yusuf ...

Please provide your email address to receive an email when new articles are posted on . EULAR has released an update to its 2008 recommendations for the management of Behçet’s syndrome, which adds new ...

PRINCETON, N.J., Feb. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

PRINCETON, N.J., July 31, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

Behçet's disease (BD) is a multisystem inflammatory disorder currently classified as a vasculitis. Its etiopathogenesis is unclear, but environmental, genetic and autoimmune factors have been ...

Soligenix Inc (NASDAQ:SNGX) shares rose 5.2% on Thursday after the company released positive findings from a Phase 2a ...

Although BD may affect almost any system of the body with exacerbations and remissions of inflammation, the key clinical manifestations are recurrent oral aphthous ulcers, genital ulcers, uveitis and ...

PRINCETON, N.J., Aug. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

Behçet's disease is a complex, multisystem inflammatory disorder characterised by recurrent mucocutaneous lesions, ocular involvement, and vascular, neurological, and gastrointestinal manifestations.